Molecular pathogenesis of severe acute respiratory syndrome

Abstract The global outbreak in 2002–2003 of severe acute respiratory syndrome (SARS) posed a serious threat to public health and had a significant impact on socioeconomic stability. Although the global outbreak of SARS has been contained, there are serious concerns over its re-emergence and bioterrorism potential, and up to date, no specific treatment exists for this disease. Here we review the progress of studies on the pathogenesis of the disease, in particular, studies on the molecular level.

[1]  P. Palese,et al.  7a Protein of Severe Acute Respiratory Syndrome Coronavirus Inhibits Cellular Protein Synthesis and Activates p38 Mitogen-Activated Protein Kinase , 2006, Journal of Virology.

[2]  Anil T Ahuja,et al.  Severe acute respiratory syndrome: radiographic appearances and pattern of progression in 138 patients. , 2003, Radiology.

[3]  A. Steinkasserer,et al.  DC-SIGN and DC-SIGNR Interact with the Glycoprotein of Marburg Virus and the S Protein of Severe Acute Respiratory Syndrome Coronavirus , 2004, Journal of Virology.

[4]  T. Hirano,et al.  Tyrosine dephosphorylation of STAT3 in SARS coronavirus‐infected Vero E6 cells , 2004, FEBS Letters.

[5]  Mark Chappell,et al.  A crucial role of angiotensin converting enzyme 2 (ACE2) in SARS coronavirus–induced lung injury , 2005, Nature Medicine.

[6]  Y. Guan,et al.  Unique and Conserved Features of Genome and Proteome of SARS-coronavirus, an Early Split-off From the Coronavirus Group 2 Lineage , 2003, Journal of Molecular Biology.

[7]  Arthur S Slutsky,et al.  Angiotensin-converting enzyme 2 protects from severe acute lung failure , 2005, Nature.

[8]  C. Fraser,et al.  Epidemiological determinants of spread of causal agent of severe acute respiratory syndrome in Hong Kong , 2003, The Lancet.

[9]  T. Mizutani,et al.  Regulation of p90RSK phosphorylation by SARS‐CoV infection in Vero E6 cells , 2006, FEBS Letters.

[10]  G. Gao,et al.  SARS coronavirus induces apoptosis in Vero E6 Cells , 2004, Journal of medical virology.

[11]  Wenhui Li,et al.  Evaluation of Human Monoclonal Antibody 80R for Immunoprophylaxis of Severe Acute Respiratory Syndrome by an Animal Study, Epitope Mapping, and Analysis of Spike Variants , 2005, Journal of Virology.

[12]  S. Harrison,et al.  SARS Coronavirus, but Not Human Coronavirus NL63, Utilizes Cathepsin L to Infect ACE2-expressing Cells , 2006, Journal of Biological Chemistry.

[13]  Obi L. Griffith,et al.  The Genome Sequence of the SARS-Associated Coronavirus , 2003, Science.

[14]  F. Taguchi.  [SARS coronavirus]. , 2003, Uirusu.

[15]  J. A. Comer,et al.  A novel coronavirus associated with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[16]  M. Chan-yeung,et al.  A cluster of cases of severe acute respiratory syndrome in Hong Kong. , 2003, The New England journal of medicine.

[17]  Christian Drosten,et al.  Characterization of a Novel Coronavirus Associated with Severe Acute Respiratory Syndrome , 2003, Science.

[18]  Larissa B. Thackray,et al.  CD209L (L-SIGN) is a receptor for severe acute respiratory syndrome coronavirus. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[19]  Elizabeth Rea,et al.  Clinical features and short-term outcomes of 144 patients with SARS in the greater Toronto area. , 2003, JAMA.

[20]  Gary J. Nabel,et al.  A DNA vaccine induces SARS coronavirus neutralization and protective immunity in mice , 2004, Nature.

[21]  Chengsheng Zhang,et al.  Receptor and viral determinants of SARS-coronavirus adaptation to human ACE2 , 2005, The EMBO journal.

[22]  Renji Reghunathan,et al.  Expression profile of immune response genes in patients with Severe Acute Respiratory Syndrome , 2005, BMC Immunology.

[23]  J. Sung,et al.  Retrospective comparison of convalescent plasma with continuing high‐dose methylprednisolone treatment in SARS patients , 2004, Clinical Microbiology and Infection.

[24]  K. Subbarao,et al.  pH-Dependent Entry of Severe Acute Respiratory Syndrome Coronavirus Is Mediated by the Spike Glycoprotein and Enhanced by Dendritic Cell Transfer through DC-SIGN , 2004, Journal of Virology.

[25]  S. Harrison,et al.  Structure of SARS Coronavirus Spike Receptor-Binding Domain Complexed with Receptor , 2005, Science.

[26]  L. Poon,et al.  Clinical progression and viral load in a community outbreak of coronavirus-associated SARS pneumonia : a prospective study , 2003 .

[27]  G. Navis,et al.  Tissue distribution of ACE2 protein, the functional receptor for SARS coronavirus. A first step in understanding SARS pathogenesis , 2004, The Journal of pathology.

[28]  Christian Drosten,et al.  Identification of a novel coronavirus in patients with severe acute respiratory syndrome. , 2003, The New England journal of medicine.

[29]  A. Debnath,et al.  Interaction between heptad repeat 1 and 2 regions in spike protein of SARS-associated coronavirus: implications for virus fusogenic mechanism and identification of fusion inhibitors , 2004, The Lancet.

[30]  John L. Sullivan,et al.  Angiotensin-converting enzyme 2 is a functional receptor for the SARS coronavirus , 2003, Nature.

[31]  J. Sung,et al.  Haematological manifestations in patients with severe acute respiratory syndrome: retrospective analysis , 2003, BMJ : British Medical Journal.

[32]  W. Mak,et al.  Homozygous L-SIGN (CLEC4M) plays a protective role in SARS coronavirus infection , 2005, Nature Genetics.

[33]  Chi-kong Li,et al.  Hematological findings in SARS patients and possible mechanisms (review). , 2004, International journal of molecular medicine.

[34]  Z. Lang,et al.  Pathological study on severe acute respiratory syndrome. , 2003, Chinese medical journal.

[35]  Jia-hai Lu,et al.  Severe acute respiratory syndrome: vaccine on the way. , 2005, Chinese medical journal.

[36]  Yi Guan,et al.  Lung pathology of fatal severe acute respiratory syndrome , 2003, The Lancet.